India Activists Claim U.S. Steps Up Lobbying Against Compulsory License
02:00 EDT 17 Jul 2012 | Elsevier Business Intelligence
Foreign drug makers complaining about India's use of its compulsory licensing law to allow a generic of a Bayer patent-protected cancer drug appear to have the active backing of the U.S. government.
Original Article: India Activists Claim U.S. Steps Up Lobbying Against Compulsory License
More From BioPortfolio on "India Activists Claim U.S. Steps Up Lobbying Against Compulsory License"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
